After a US regulator approved its use in adults and adolescents, people at risk of contracting HIV will now have an injectable choice for pre-exposure prophylaxis (Prep).
The injectable medicine cabotegravir, marketed under the trade name Apretude, is the first-ever injectable HIV Prep option that at-risk individuals will take at two-month intervals.
The Food and Drug Administration has placed a restriction on its use, requiring that the user be HIV-negative and weigh at least 35 kilogrammes.
Other kinds of PrEP that were taken by HIV negative at-risk individuals before this approval were daily pills, of which only two types— Truvada and Descovy— had been approved for usage.
“Today’s clearance adds an essential tool to the battle to end the HIV epidemic by giving the first HIV prevention option that does not require daily pill consumption,” Debra added.
